Emergency Complications Associated with Chemotherapeutics and Cancer

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 25, Issue 9, 2003, Pages 676-688

  Michael Walters, J ^a   Connally, Heather E ^a   Ogilvie, Gregory K ^a   Hackett, Timothy B ^a   Mazzaferro, Elisa M ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Denver Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141976224     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Kisseberth WC, MacEwen EG: Complications of cancer and its treatment, in Withrow SJ, MacEwen EG (eds): Small Animal Clinical Oncology, ed 3. Philadelphia, WB Saunders, 2001, pp 198-219.
2. Wohl JS, Cotter SM: Approach to complications of anti-cancer therapy in emergency practice. J Vet Emerg Crit Can 5(1):61-76, 1995.
3. Couto CG: Management of complications of chemotherapy. Vet Clin North Am Small Anim Pract 20(4):1037-1053, 1990.
4. Kirby R: Septic shock, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XII. Philadelphia, WB Saunders, 1995, pp 139-146.
5. Lagutchik MS: Fever in the ICU patient, in Wingfield WE, Raffe MR (eds): The Veterinary ICU Book. Jackson, WY, Teton NewMedia, 2002, pp 671-684.
6. Marino PL: The febrile patient, in Marino PL (ed): The ICU Book, ed 2. Baltimore, Williams & Wilkins, 1998, pp 485-501.
7. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6):864-874, 1992.
8. Brady CA, Otto CM: Systemic inflammatory response syndrome, and multiple organ dysfunction. Vet Clin North Am Small Anim Pract 31(6):1147-1162, 2001.
9. Otto C: Sepsis, in Wingfield WE, Raffe MR (eds): The Veterinary ICU Book. Jackson, WY, Teton NewMedia, 2002, pp 695-709.
10. Hackett TB: Multiorgan failure, in Wingfield WE, Raffe MR (eds): The Veterinary ICU Book. Jackson, WY, Teton NewMedia, 2002, pp 685-694.
11. Couto CG: Combined cytopenias and leukoerythroblastosis, in Nelson RW, Couto CG (eds): Small Animal Internal Medicine, ed 2. St. Louis, Mosby, 1998, pp 1187-1191.
12. Wyatt KM, Wyatt GL: Evaluation of a manual technique of detection of neutropenia and thrombocytopenia in dogs receiving chemotherapy. JAVMA 220(12):1805-1806, 2002.
13. Dow SW, Curtis CR, Jones RL, Wingfield WE: Bacterial culture of blood from critically ill dogs and cats: 100 cases (1985-1987). JAVMA 195:113-117, 1989.
14. Abrams-Ogg ACG, Kruth SA: Antimicrobial therapy of the neutropenic dog and cat, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XIII. Philadelphia, WB Saunders, 2000, pp 267-272.
15. Moore K, Murtaugh RJ: Pathophysiologic characteristics of hypovolemic shock. Vet Clin North Am Small Anim Pract 31 (6): 1115-1128, 2001.
16. Butt W: Septic shock. Pediatr Clin North Am 48(3):601-625, 2001.
17. Marik PE, Varon J: Sepsis: State of the art. Dis Mon 47(10): 465-532, 2001.
18. Aucoin DP: Rational use of antimicrobial drugs, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XII. Philadelphia, WB Saunders, 1995, pp 207-211.
19. Lappin MR: Practical antimicrobial chemotherapy, in Nelson RW, Couto CG (eds): Small Animal Internal Medicine, ed 2. St. Louis, Mosby, 1998, pp 1253-1264.
20. Rassnick KM: Toxicology of antineoplastic treatments, in Wing-field WE, Raffe MR (eds): The Veterinary ICU Book. Jackson, WY, Teton NewMedia, 2002, pp 1137-1146.
21. Gasper PW: The hematopoietic system, in Feldman BF, Zinkl JG, Jain NC (eds): Schalm's Veterinary Hematology. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 63-68.
22. Kaelin Jr WG, Mayer RJ: Hematologic complications of cancer and cancer therapy, in Moosa AR, Schimpft SC, Robson MC (eds): Comprehensive Textbook on Oncology. Baltimore, Williams & Wilkins, 1991, pp 1754-1760.
23. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862-871, 2002.
24. Prittie JE, Barton LJ, Peterson ME, et al: Pituitary ACTH and adrenocortical secretion in critically ill dogs. JAVMA 220(5): 615-619, 2002.
25. Dow SW, Jones RL: Bactetemia: Pathogenesis and diagnosis. Compend Contin Educ Pract Vet 11:432-443, 1989.
26. Ogilvie GK, Obradovich JE, Cooper MF, et al: Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog. J Vet Intern Mat 6:44-47, 1992.
27. Walton SM: Therapeutic use of colony-stimulating factors for established neutropenic fever. W V Med J 94:26-28, 1998.
28. Henry CJ, Buss MS, Lothrup CD: Veterinary use of recombinant human granulocyte colony-stimulating factor: Part I: Oncology. Compend Contin Educ Pract Vet 20:728-735, 1998.
29. Rewerts JM, McCaw DL, Cohn LA, et al: Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. JAVMA 213(7):991-992, 1998.
30. van der Poll T: Immunotherapy of sepsis. Lancet 1:165-174, 2001.
31. Attalah HL, Azoulay E, Yang K, et al: Granulocyte colony-stimulating facror enhances the host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 30(9):2107-2114, 2002.
32. Eichacker PQ, Waisman Y, Natanson C, et al: Cardiopulmonary effects of granulocyte colony-stimulating factor in a canine model of bacterial sepsis. J Appl Physiol 77(5)-2366-2377, 1994.
33. Natanson C, Hoffman WD, Suffredini AF, et al: Selected treatment strategies for septic shock based on proposed mechanism of pathogenesis. Ann Intern Med 120(9):771-783, 1994.
34. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585, 2000.
35. Quezado ZMN, Eichacker PQ: Prophylactic granulocyte colony-stimulating factor in the critically ill: Carefully balancing the benefits and risks. Crit Care Med 30(9):2162-2164, 2002.
36. Plumb DC: Veterinary Drug Handbook, ed 3. Ames, Iowa State University Press, 1999.
37. Bezek DM: Use of prochlorperazine in treatment of emesis in dogs. Canine Pract 23(4):8-9, 1998.
38. Ogilvie GK: Dolasetron: A new option for nausea and vomiting. JAAHA 36(6):481-483, 2000.
39. Macintire DK: Bacterial translocation: Clinical implications and prevention, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XIII. Philadelphia, WB Saunders, 2000, pp 201-203.
40. Cook AK, Breitschwerdt EB, Levine JF, et al: Risk factors associated with acute pancreatitis in dogs: 101 cases (1985-1990). JAVMA 203:673-679, 1993.
41. Tolba KA, Deliargyris EN: Cardiotoxicity of cancer therapy. Cancer Invest 17(6):408-422, 1999.
42. Mauldin GE, Fox PR, Patniak AK, et al: Doxorubicin-induced cardiotoxicosis - clinical features in 32 dogs. J Vet Intern Med 6: 82-88, 1992.
43. O'Keefe DA, Sisson DD, Gelberg HB, et al: Systemic toxicity associated with doxorubicin administration in cats. J Vet Intern Med 7:309-317, 1993.
44. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58, 1996.
45. Herman EH, Ferrans VJ: Preclinical animal models of cardiac protection from anthtacycline-induced cardiotoxicity. Semin Oncol 25:15-21, 1998.
46. Hassinoff BB, Hellmann EHH, Ferrans VJ: Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28, 1998.
47. th IVECCS:74-78, 2002.
48. Sisson D, Kittleson M: Management of heart failure: Principles of treatment, therapeutic strategies, and pharmacology, in Fox PR, Sisson D, Moise NS (eds): Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, ed 2. Philadelphia, WB Saunders, 1999, pp 216-250.
49. Dorman DC, Coddington KA. Richardson RC: 5-Fluorouracil toxicosis in the dog. J Vet Intern Med 4:254-257, 1990.
50. Roberts J, Powell LL: Accidental 5-fluorouracil exposure in a dog. J Vet Emerg Crit Care 11 (4):281-286, 2001.
51. Swanson JF, Morgan S, Green WR, et al: Cerebral thrombosis and hemorrhage in association with L-asparaginase administration. JAAHA 22:749-755, 1986.
52. Chun R, Garrett L, MacEwen EG: Cancer chemotherapy, in Withrow SJ, MacEwen EG (eds): Small Animal Clinical Oncology, ed 3. Philadelphia, WB Saunders, 2001, pp 92-118.
53. Crow SE, Theilen GH, Madewell BR, et al: Cyclophosphamide-induced cystitis in the dog and cat JAVMA 171:259-262, 1977.
54. Peterson JL, Couto CG, Hammer AS, et al: Acute sterile hemorrhagic cystitis after a single intravenous administration of cyclophosphamide in three dogs. JAVMA 201:1572-1574, 1992.
55. Laing EJ, Miller CW, Cochrane SM: Treatment of cyclophosphamide-induced hemorrhagic cystitis in five dogs. JAVMA 193:233-236, 1988.
56. Heness JF: Treatment of cyclophosphamide-induced cystitis. JAVMA 187:4-5, 1985.
57. Spugnini E: Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. JAVMA 221(10): 1437-1440, 2002.
58. Albanell J, Baselga J: Systemic therapy emergencies. Semin Oncol 27:347-361, 2000.
59. Disa JJ, Chang RR, Mucci SJ, et al: Prevention of adriamycin-induced full thickness skin loss using hvaluronidase infiltration. Plast Reconstr Surg 101:370-374, 1998.
60. Langer SW, Sehested M, Jensen PB: Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6:3680-3686, 2000.
61. Laing EJ, Carter RF: Acute tumor lysis syndrome following treatment for canine lymphoma. JAAHA 24:691-696, 1987.
62. Jasek AM, Day HJ: Acute spontaneous tumor lysis syndrome. Am J Hematol 47:129-131, 1994.